Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis / S. Villani, N. Zanotta, F. Ambrogi, M. Comar, D. Franciotta, M. Dolci, C. Cason, R. Ticozzi, P. Ferrante, S. Delbue. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 310(2017 Sep 15), pp. 91-96.
|Titolo:||Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis|
|Parole Chiave:||Cytokines; JC virus; Natalizumab; Adult; Antibodies, Viral; Cytokines; Female; Follow-Up Studies; Humans; Immunologic Factors; Intercellular Signaling Peptides and Proteins; JC Virus; Male; Multiple Sclerosis; Natalizumab; T-Lymphocyte Subsets; Time Factors; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)|
|Settore Scientifico Disciplinare:||Settore MED/07 - Microbiologia e Microbiologia Clinica|
|Progetto:||Tecnologie OMICS e Systems Biology per la definizione di nuove strategie finalizzate al controllo delle infezioni virali|
|Data di pubblicazione:||15-set-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.jneuroim.2017.06.012|
|Appare nelle tipologie:||01 - Articolo su periodico|